Neuroendocrine cancer medicine
Neuroendocrine cancer medicine of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase.
- Cancer la colon manifestari
- Hpv head and neck cancer
They change related to the disease progression, regardless therapy. Some of the drugs that are used for NETs as somatostatin analogs for example octreotide might interfere with glucose neuroendocrine cancer medicine.
Most Downloaded Articles
We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile. Material and Methods. All the patients had at least one assay per neuroendocrine cancer medicine.
The dose of octreotide varied from 20 to 50 mg, monthly.
The fasting glucose insignificantly changed from baseline after 2 years. No new case of diabetes was registered. One case of known diabetes needed insulin but interferon therapy was also added during this time period. The chromogranin A had sustained high values neuroendocrine cancer medicine all the 9 cases, marking the disease progression.
- Virus papiloma la barbati
- Neuroendocrine cancer diarrhea
The neuron specific enolase significantly increased, and the serum serotonin as well as the 5HIIA was much higher in 2 cases with aggressive carcinoid symptoms. The NET markers and the glucose metabolism are most useful tools in the management of NETs, yet they are not correlated.
Neuroendocrine tumors.
Endocr Relat Cancer. DOI: Oberndorfer S.
Karzinoide tumoren des dunndarms. Frank Z Pathol. Carcinoid Tumors.
Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnosis immunohistochemistry. Adv Anat Pathol. Chromogranins A B C: widespread consitituents of secretory vesicles.
Revista Romana de Medicina de Laborator
Ann N Y Acad Sci. Chromogranin A neuron specific enolase carcinoembryonic antigen and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.
CO; 8. Regul Pept.
The poor prognosis factors in G2 neuroendocrine tumor. Rom J Morphol Embryol.
The dedifferentiation of neuroendocrine tumor metastases: myth or reality? Octreotide for the treatment of hypoglycemia after insulin glargine overdose.
J Emerg Med. Biochemical testing for neuroendocrine tumors.
The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am ;40 1 Well-differentiated neuroendocrine tumor and osteoporosis: incidental cancer san agresiv Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide.
Acta Oncol.
Long-term clinical outcome of somatostatin analogues for treatment of pregressive metastatic well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.
